Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 6, 2006 - Issue 2
Submit an article Journal homepage
117
Views
8
CrossRef citations to date
0
Altmetric
Review

BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance

Xiaowei Chen Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, PA 19111-2409, USA. [email protected]
,
Cletus A Arciero Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, PA 19111-2409, USA. [email protected]
&
Andrew K Godwin Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, PA 19111-2409, USA. [email protected]
Pages 187-196 | Published online: 10 Jan 2014

References

  • Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10–30 (2005).
  • King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643–646 (2003).
  • Antoniou AC, Pharoah PD, Narod S et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J. Med. Genet. 42(7), 602–603 (2005).
  • Bove B, Dunbrack R, Godwin AK. BRAC1, BRAC2, and hereditary breast cancer. In: Breast Cancer: Prognosis, Treatment and Prevention. Pasqualini J (Ed.). Marcel Dekker, Inc., NY, USA (2002).
  • Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16(1), 64–67 (1997).
  • Vahteristo P, Tamminen A, Karvinen P et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 61(15), 5718–5722 (2001).
  • Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182), 66–71 (1994).
  • Futreal PA, Liu Q, Shattuck-Eidens D et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266(5182), 120–122 (1994).
  • Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon DJ. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int. J. Cancer 80(6), 823–826 (1999).
  • Yang Q, Sakurai T, Mori I et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 92(1), 54–60 (2001).
  • Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917–921 (2005).
  • Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl Cancer Inst. 94(13), 990–1000 (2002).
  • Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem. 274(26), 18808–18812 (1999).
  • Foray N, Randrianarison V, Marot D, Perricaudet M, Lenoir G, Feunteun J. γ-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene 18(51), 7334–7342 (1999).
  • Mamon HJ, Dahlberg W, Azzam EI, Nagasawa H, Muto MG, Little JB. Differing effects of breast cancer 1(BRCA1), early onset and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation. Int. J. Radiat. Biol. 79(10), 817–829 (2003).
  • Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl Acad. Sci. USA 98(9), 5134–5139 (2001).
  • Shen SX, Weaver Z, Xu X et al. A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability. Oncogene 17(24), 3115–3124 (1998).
  • Lynch HT, Krush AJ. Carcinoma of the breast and ovary in three families. Surg. Gynecol. Obstet. 133(4), 644–648 (1971).
  • Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988), 1684–1689 (1990).
  • Lu M, Conzen SD, Cole CN, Arrick BA. Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells. Cancer Res. 56(20), 4578–4581 (1996).
  • Wilson CA, Payton MN, Elliott GS et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-δ11b. Oncogene 14(1), 1–16 (1997).
  • Bienstock RJ, Darden T, Wiseman R, Pedersen L, Barrett JC. Molecular modeling of the amino-terminal zinc ring domain of BRCA1. Cancer Res. 56(11), 2539–2545 (1996).
  • Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH. The nuclear localization sequences of the BRCA1 protein interact with the importin-α subunit of the nuclear transport signal receptor. J. Biol. Chem. 271(51), 32863–32868 (1996).
  • Callebaut I, Mornon JP. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett. 400(1), 25–30 (1997).
  • Frank TS, Manley SA, Olopade OI et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol. 16(7), 2417–2425 (1998).
  • Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15), 1242–1250 (1997).
  • Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet. 75(4), 535–544 (2004).
  • Phelan CM, Dapic V, Tice B et al. Classification of BRCA1 missense variants of unknown clinical significance. J. Med. Genet. 42(2), 138–146 (2005).
  • Ruffner H, Verma IM. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc. Natl Acad. Sci. USA 94(14), 7138–7143 (1997).
  • Thakur S, Zhang HB, Peng Y et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol. Cell Biol. 17(1), 444–452 (1997).
  • Scully R, Chen J, Ochs RL et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90(3), 425–435 (1997).
  • Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59(Suppl. 7), S1752–S1756 (1999).
  • Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol. Cell 4(6), 1093–1099 (1999).
  • Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61(12), 4842–4850 (2001).
  • Kote-Jarai Z, Salmon A, Mengitsu T et al. Increased level of chromosomal damages after irradiation of lymphocytes from BRCA1 mutation carriers. Br. J. Cancer (In press) (2005).
  • Zhong Q, Boyer TG, Chen PL, Lee WH. Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res. 62(14), 3966–3970 (2002).
  • Zhong Q, Chen CF, Chen PL, Lee WH. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J. Biol. Chem. 277(32), 28641–28647 (2002).
  • Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nature Genet. 32(1), 180–184 (2002).
  • Somasundaram K, Zhang H, Zeng YX et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389(6647), 187–190 (1997).
  • Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nature Genet. 30(3), 285–289 (2002).
  • Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of Brca1 (5–6) early embryonic lethality by p53 or p21 null mutation. Nature Genet. 16(3), 298–302 (1997).
  • Xu X, Weaver Z, Linke SP et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3(3), 389–395 (1999).
  • Xu X, Qiao W, Linke SP et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genet. 28(3), 266–271 (2001).
  • Shorrocks J, Tobi SE, Latham H et al. Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. Int. J. Radiat. Oncol. Biol. Phys. 58(2), 470–478 (2004).
  • Wu LC, Wang ZW, Tsan JT et al. Identification of a RING-protein that can interact in vivo with the BRCA1 gene product. Nature Genet. 14(4), 430–440 (1996).
  • Hashizume R, Fukuda M, Maeda I et al. The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276(18), 14537–14540 (2001).
  • Scully R, Anderson SF, Chao DM et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc. Natl Acad. Sci. USA 94(11), 5605–5610 (1997).
  • Kleiman FE, Wu-Baer F, Fonseca D, Kaneko S, Baer R, Manley JL. BRCA1/BARD1 inhibition of mRNA 3´ processing involves targeted degradation of RNA polymerase II. Genes Dev. 19(10), 1227–1237 (2005).
  • Starita LM, Horwitz AA, Keogh MC, Ishioka C, Parvin JD, Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J. Biol. Chem. 280(26), 24498–24505 (2005).
  • Dong Y, Hakimi MA, Chen X et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell 12(5), 1087–1099 (2003).
  • Sato K, Hayami R, Wu W et al. Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J. Biol. Chem. 279(30), 30919–30922 (2004).
  • Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14(8), 927–939 (2000).
  • Bochar DA, Wang L, Beniya H et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102(2), 257–265 (2000).
  • Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl Acad. Sci. USA 96(9), 4983–4988 (1999).
  • Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J. Natl Cancer Inst. 96(22), 1659–1668 (2004).
  • Scully R, Xie A, Nagaraju G. Molecular functions of BRCA1 in the DNA damage response. Cancer Biol. Ther. 3(6), 521–527 (2004).
  • Fletcher GH. Local results of irradiation in the primary management of localized breast cancer. Cancer 29(3), 545–551 (1972).
  • Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 333(22), 1456–1461 (1995).
  • Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 347(16), 1233–1241 (2002).
  • Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 347(16), 1227–1232 (2002).
  • Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503), 2087–2106 (2006).
  • Kurtz JM, Amalric R, Brandone H et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer 63(10), 1912–1917 (1989).
  • Smith TE, Lee D, Turner BC, Carter D, Haffty BG. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int. J. Radiat. Oncol. Biol. Phys. 48(5), 1281–1289 (2000).
  • Canman CE, Lim DS, Cimprich KA et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281(5383), 1677–1679 (1998).
  • Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286(5442), 1162–1166 (1999).
  • Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404(6774), 201–204 (2000).
  • Tibbetts RS, Brumbaugh KM, Williams JM et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13(2), 152–157 (1999).
  • Zhong Q, Chen CF, Li S et al. Association of BRCA1 with the hRad50–hMre11–p95 complex and the DNA damage response. Science 285(5428), 747–750 (1999).
  • Baeyens A, Thierens H, Claes K, Poppe B, de Ridder L, Vral A. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int. J. Radiat. Biol. 80(10), 745–756 (2004).
  • Garcia-Higuera I, Taniguchi T, Ganesan S et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7(2), 249–262 (2001).
  • Leong T, Whitty J, Keilar M et al. Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 48(4), 959–965 (2000).
  • Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur. J. Cancer 41(15), 2304–2311 (2005).
  • Pierce LJ, Strawderman M, Narod SA et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J. Clin. Oncol. 18(19), 3360–3369 (2000).
  • Billecke CA, Ljungman ME, McKay BC, Rehemtulla A, Taneja N, Ethier SP. Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. Oncogene 21(29), 4481–4489 (2002).
  • Boulton SJ, Martin JS, Polanowska J, Hill DE, Gartner A, Vidal M. BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans. Curr. Biol. 14(1), 33–39 (2004).
  • Carlson CA, Ethier SP. Lack of RB protein correlates with increased sensitivity to UV-radiation-induced apoptosis in human breast cancer cells. Radiat. Res. 154(5), 590–599 (2000).
  • Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 62(1), 223–229 (2005).
  • Digweed M, Demuth I, Rothe S et al. SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. Oncogene 21(32), 4873–4878 (2002).
  • Houghtaling S, Newell A, Akkari Y, Taniguchi T, Olson S, Grompe M. Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. Hum. Mol. Genet. 14(20), 3027–3033 (2005).
  • Lio YC, Schild D, Brenneman MA, Redpath JL, Chen DJ. Human Rad51C deficiency destabilizes XRCC3, impairs recombination, and radiosensitizes S/G2-phase cells. J. Biol. Chem. 279 (40), 42313–42320 (2004).
  • Nakanishi K, Taniguchi T, Ranganathan V et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nature Cell Biol. 4(12), 913–920 (2002).
  • Russell JS, Brady K, Burgan WE et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 63(21), 7377–7383 (2003).
  • Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 26(12), 2859–2864 (1998).

Website

  • Breast Cancer Information Core (BIC) http://research.nhgri.nih.gov/bic/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.